Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Menthol + tretinoin + zinc oxide is a topical combination pharmaceutical product marketed as **DERMAWERX ZMT PAK**. It is a kit-based formulation manufactured for Rouses Point Pharmaceuticals that combines tretinoin, a small-molecule retinoid used as the principal anti-acne agent, with menthol as an external analgesic and anti-itch component and zinc oxide as a skin protectant. In this combination, tretinoin drives the therapeutic effect in acne vulgaris by normalizing epidermal differentiation and accelerating turnover of follicular epithelial cells, thereby promoting comedolysis and reducing acne lesion formation, while menthol and zinc oxide provide supportive topical symptom-relief and barrier-protective functions. The tretinoin component is applied once daily at bedtime to affected skin, and the overall product is intended for external topical use only.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on menthol + tretinoin + zinc oxide.